Cargando…
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
BACKGROUND: In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their clinical u...
Autores principales: | Semmlinger, Anna, von Schoenfeldt, Viktoria, Wolf, Verena, Meuter, Alexandra, Kolben, Theresa Maria, Kolben, Thomas, Zeder-Goess, Christine, Weis, Florian, Gallwas, Julia, Wuerstlein, Rachel, Hermelink, Kerstin, Schmoeckel, Elisa, Harbeck, Nadia, Mayr, Doris, Mahner, Sven, Jeschke, Udo, Ditsch, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902996/ https://www.ncbi.nlm.nih.gov/pubmed/29661238 http://dx.doi.org/10.1186/s12885-018-4286-9 |
Ejemplares similares
-
Expression of H3K4me3 and H3K9ac in breast cancer
por: Berger, Luisa, et al.
Publicado: (2020) -
EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
por: Hester, Anna, et al.
Publicado: (2019) -
High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients
por: Trebo, Anna, et al.
Publicado: (2020) -
The role of E-Cadherin expression in primary site of breast cancer
por: Karsten, Nora, et al.
Publicado: (2021) -
The role of EP-2 receptor expression in cervical intraepithelial neoplasia
por: Schmoeckel, Elisa, et al.
Publicado: (2020)